Steven L Shein1, Richard H Speicher1, Alexandre T Rotta1. 1. Divisão de Terapia Intensiva Pediátrica, UH Rainbow Babies & Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
We thank Drs. Colleti Jr and Carvalho for their interest in our recent publication in
Revista Brasileira de Terapia Intensiva .( We agree that avoidance of mechanical
ventilation (MV) is preferable in pediatric intensive care unit (PICU) patients with
critical asthma, but primarily to avoid MV-associated morbidity, as MV-associated
mortality is exceptionally rare in the current era. Newth recently reported a mortality
rate of 4.3% for children with near-fatal asthma in United States PICUs, which is lower
than the 9.4% mortality rate among adults hospitalized nearly 2 decades ago with
near-fatal asthma that was reported in the paper cited by Colleti Jr and
Carvalho.( Moreover, 10 of the 11 children who died in the recent
PICU study had suffered cardiac arrest prior to the PICU admission and neurologic injury
was the cause of death in nearly all of them, not intractable pulmonary
disease.( Still, our practice
is to avoid MV whenever possible in children with critical asthma.High-flow nasal cannula (HFNC) has been associated with favorable outcomes in many
patient groups, including premature neonates, young children with bronchiolitis, and
adults with acute hypoxemic respiratory failure.( HFNC primarily improves
gas exchange by washing out dead space, and also causes positive pharyngeal pressures
that may be transmitted somewhat to the distal airways and cause a low-level of positive
end-expiratory pressure (PEEP). Positive airway pressure effects of HFNC are extremely
dependent on patient size, cannula diameter, and HFNC flow rate. Pharyngeal pressures of
5 to 7cmH2O have been generated at 5 to 8L/minute in premature neonates
weighing ~1 to 4kg, but flows of 50L/minute are needed to generate similar pressures in
adult-sized patients.( It is unclear how much of that pharyngeal pressure is
actually transmitted to the alveoli, but it is thought to be clinically insignificant
under usual flows and in the range of ~1cmH2O, thus too low to fully explain
the observed clinical benefits.(
Furthermore, generation of single-level PEEP (as opposed to BiPAP) in asthma may worsen
hyperinflation without assisting inspiratory work, leading some to suggest that HFNC
should be avoided in asthma.( While
we do not believe that HFNC is contraindicated in asthma since dead space washout may be
helpful and generation of PEEP is likely trivial at typical flow rates, there are
insufficient data reporting use of HFNC in PICU patients with critical asthma for us to
have included it in our review. Hopefully, now that devices are available that allow for
concurrent use of HFNC and continuous nebulized albuterol without the introduction of
unconditioned bias flow to the circuit (i.e., Aerogen nebulizer), literature describing
its use in pediatric critical asthma will likely become available.We thank Colleti Jr and Carvalho for commenting on the use of intravenous magnesium in
patients with critical asthma. Several studies performed in the emergency department
setting show associations between magnesium infusions and favorable outcomes, including
the provocative paper by Irazuzta cited by Colleti Jr and Carvalho (published after
submission of our manuscript).( Our
focus was not pediatric asthma care in the emergency department, but the treatment of
critical and near-fatal asthma in the PICU. Unfortunately, there is insufficient
evidence to fully support the routine use magnesium in this latter cohort. Colleti Jr
and Carvalho noted that other authors have reported different dosing strategies than
ours (25 - 40mg/kg), such as a bolus of 50 - 75mg/kg followed by an infusion of
40mg/kg/hour. In the one study of 19 subjects treated with that regimen cited by Colleti
Jr and Carvalho, 3 subjects (15.8%) had side effects related to its use and no
associations with clinical outcomes were reported.( More research is indeed needed on the use of both magnesium
and HFNC in children with critical asthma.Steven L Shein, Richard H Speicher and Alexandre T RottaDivision of Pediatric Critical Care Medicine, UH Rainbow Babies & Children's
Hospital, Case Western Reserve University - Cleveland, OH, United States
Authors: Trudy B Pendergraft; Richard H Stanford; Richard Beasley; David A Stempel; Craig Roberts; Trent McLaughlin Journal: Ann Allergy Asthma Immunol Date: 2004-07 Impact factor: 6.347
Authors: Sarah Rubin; Anoopindar Ghuman; Timothy Deakers; Robinder Khemani; Patrick Ross; Christopher J Newth Journal: Pediatr Crit Care Med Date: 2014-01 Impact factor: 3.624
Authors: A Schibler; T M T Pham; K R Dunster; K Foster; A Barlow; K Gibbons; J L Hough Journal: Intensive Care Med Date: 2011-03-03 Impact factor: 17.440
Authors: Christopher J L Newth; Kathleen L Meert; Amy E Clark; Frank W Moler; Athena F Zuppa; Robert A Berg; Murray M Pollack; Katherine A Sward; John T Berger; David L Wessel; Rick E Harrison; Jean Reardon; Joseph A Carcillo; Thomas P Shanley; Richard Holubkov; J Michael Dean; Allan Doctor; Carol E Nicholson Journal: J Pediatr Date: 2012-04-10 Impact factor: 4.406
Authors: Steven L Shein; Richard H Speicher; José Oliva Proença Filho; Benjamin Gaston; Alexandre T Rotta Journal: Rev Bras Ter Intensiva Date: 2016-06